DUPA

Research use only, not for human use.

DUPA is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

DUPA is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.(In Vitro):After binding to a DUPA-drug conjugate, PSMA internalizes, unloads the conjugate, and returns to the surface.(In Vivo):As determined by loss of body weight and death of treated mice,DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity.

DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer. The DUPA-indenoisoquinoline conjugate exhibits an IC50 in the low nanomolar range in 22RV1 cell cultures.

The DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity, as determined by loss of body weight and death of treated mice.

(2S,2'S)-2,2'-Carbonylbis(Azanediyl)Dipentanedioic Acid | N,N''-Carbonylbis[L-glutamic acid]

Others

Other Targets

20S proteasome

——

——

302941-52-2

320.254

C11H16N2O9

>98% (HPLC)

In Vitro:?DMSO : ≥ 300 mg/mL (936.77 mM)

[H][C@@](CCC(O)=O)(NC(=O)N[C@@]([H])(CCC(O)=O)C(O)=O)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years